|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: XYLT1 |
Gene summary for XYLT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | XYLT1 | Gene ID | 64131 |
| Gene name | xylosyltransferase 1 | |
| Gene Alias | DBQD2 | |
| Cytomap | 16p12.3 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q86Y38 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64131 | XYLT1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.27e-07 | -4.59e-01 | 0.0155 |
| 64131 | XYLT1 | HTA11_7696_3000711011 | Human | Colorectum | AD | 4.64e-04 | -3.57e-01 | 0.0674 |
| 64131 | XYLT1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 8.73e-23 | -6.66e-01 | 0.294 |
| 64131 | XYLT1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.48e-03 | -3.75e-01 | 0.3859 |
| 64131 | XYLT1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.97e-14 | -5.94e-01 | 0.3005 |
| 64131 | XYLT1 | F007 | Human | Colorectum | FAP | 5.02e-05 | -4.09e-01 | 0.1176 |
| 64131 | XYLT1 | A002-C-010 | Human | Colorectum | FAP | 4.03e-04 | -4.16e-01 | 0.242 |
| 64131 | XYLT1 | A001-C-207 | Human | Colorectum | FAP | 1.53e-08 | -4.68e-01 | 0.1278 |
| 64131 | XYLT1 | A015-C-203 | Human | Colorectum | FAP | 7.87e-35 | -7.02e-01 | -0.1294 |
| 64131 | XYLT1 | A015-C-204 | Human | Colorectum | FAP | 3.56e-13 | -4.84e-01 | -0.0228 |
| 64131 | XYLT1 | A014-C-040 | Human | Colorectum | FAP | 1.87e-07 | -6.25e-01 | -0.1184 |
| 64131 | XYLT1 | A002-C-201 | Human | Colorectum | FAP | 2.40e-25 | -6.04e-01 | 0.0324 |
| 64131 | XYLT1 | A002-C-203 | Human | Colorectum | FAP | 2.58e-04 | -3.41e-01 | 0.2786 |
| 64131 | XYLT1 | A001-C-119 | Human | Colorectum | FAP | 2.01e-13 | -5.81e-01 | -0.1557 |
| 64131 | XYLT1 | A001-C-108 | Human | Colorectum | FAP | 2.10e-20 | -5.57e-01 | -0.0272 |
| 64131 | XYLT1 | A002-C-205 | Human | Colorectum | FAP | 3.41e-34 | -6.95e-01 | -0.1236 |
| 64131 | XYLT1 | A001-C-104 | Human | Colorectum | FAP | 4.84e-10 | -4.68e-01 | 0.0184 |
| 64131 | XYLT1 | A015-C-005 | Human | Colorectum | FAP | 2.91e-08 | -4.42e-01 | -0.0336 |
| 64131 | XYLT1 | A015-C-006 | Human | Colorectum | FAP | 1.55e-23 | -6.82e-01 | -0.0994 |
| 64131 | XYLT1 | A015-C-106 | Human | Colorectum | FAP | 2.10e-16 | -5.24e-01 | -0.0511 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006790 | Colorectum | AD | sulfur compound metabolic process | 101/3918 | 339/18723 | 6.46e-05 | 1.07e-03 | 101 |
| GO:0001503 | Colorectum | AD | ossification | 106/3918 | 408/18723 | 7.68e-03 | 4.64e-02 | 106 |
| GO:00067902 | Colorectum | MSS | sulfur compound metabolic process | 85/3467 | 339/18723 | 1.52e-03 | 1.39e-02 | 85 |
| GO:00015032 | Colorectum | MSS | ossification | 96/3467 | 408/18723 | 6.09e-03 | 4.07e-02 | 96 |
| GO:00015033 | Colorectum | FAP | ossification | 79/2622 | 408/18723 | 1.53e-03 | 1.37e-02 | 79 |
| GO:0021700 | Colorectum | FAP | developmental maturation | 57/2622 | 280/18723 | 2.08e-03 | 1.72e-02 | 57 |
| GO:0009101 | Colorectum | FAP | glycoprotein biosynthetic process | 63/2622 | 317/18723 | 2.31e-03 | 1.86e-02 | 63 |
| GO:0060348 | Colorectum | CRC | bone development | 37/2078 | 205/18723 | 1.96e-03 | 1.96e-02 | 37 |
| GO:00217001 | Colorectum | CRC | developmental maturation | 47/2078 | 280/18723 | 2.52e-03 | 2.38e-02 | 47 |
| GO:00015034 | Colorectum | CRC | ossification | 64/2078 | 408/18723 | 2.73e-03 | 2.49e-02 | 64 |
| GO:0048706 | Colorectum | CRC | embryonic skeletal system development | 23/2078 | 121/18723 | 6.85e-03 | 4.81e-02 | 23 |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00064931 | Esophagus | ESCC | protein O-linked glycosylation | 51/8552 | 86/18723 | 7.54e-03 | 2.70e-02 | 51 |
| GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
| GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| XYLT1 | SNV | Missense_Mutation | rs146405799 | c.1328N>A | p.Arg443Gln | p.R443Q | Q86Y38 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
| XYLT1 | SNV | Missense_Mutation | rs748327396 | c.2723N>T | p.Ser908Leu | p.S908L | Q86Y38 | protein_coding | tolerated(0.05) | benign(0.288) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| XYLT1 | SNV | Missense_Mutation | novel | c.2243N>T | p.Ala748Val | p.A748V | Q86Y38 | protein_coding | tolerated(0.2) | probably_damaging(0.953) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| XYLT1 | SNV | Missense_Mutation | rs750411891 | c.1936N>A | p.Asp646Asn | p.D646N | Q86Y38 | protein_coding | deleterious(0.02) | probably_damaging(0.967) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| XYLT1 | SNV | Missense_Mutation | rs556515927 | c.1763A>G | p.Gln588Arg | p.Q588R | Q86Y38 | protein_coding | deleterious(0.01) | possibly_damaging(0.606) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| XYLT1 | SNV | Missense_Mutation | rs375891355 | c.2734N>A | p.Gly912Arg | p.G912R | Q86Y38 | protein_coding | tolerated(0.21) | benign(0.01) | TCGA-E9-A295-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| XYLT1 | deletion | Frame_Shift_Del | novel | c.987delC | p.Phe330LeufsTer82 | p.F330Lfs*82 | Q86Y38 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| XYLT1 | SNV | Missense_Mutation | rs534156689 | c.670G>A | p.Ala224Thr | p.A224T | Q86Y38 | protein_coding | tolerated_low_confidence(0.25) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| XYLT1 | SNV | Missense_Mutation | novel | c.2851N>A | p.Ala951Thr | p.A951T | Q86Y38 | protein_coding | tolerated(0.05) | benign(0.003) | TCGA-DG-A2KJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| XYLT1 | SNV | Missense_Mutation | c.2170N>T | p.Val724Phe | p.V724F | Q86Y38 | protein_coding | tolerated(0.7) | benign(0.009) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |